AI Agents That Unlock Regulated Life Sciences Workflows with LogicFlo AI

LogicFlo AI is building the AI agent workforce for life sciences, revolutionizing how experts in pharma, biotech, and medtech manage their complex, high-compliance workflows. In industries where precision and regulatory adherence are critical, LogicFlo’s intelligent agents act as personalized AI collaborators, handling tasks such as medical writing, regulatory documentation, quality control, and commercial content creation. By automating these time-consuming activities, the platform frees life sciences professionals to focus on advancing medical innovation.

Today, LogicFlo AI announced it has raised $2.7 million in seed funding, led by Lightspeed with participation from leading healthcare and enterprise AI investors. This investment will accelerate product development, deepen integration with life sciences systems like Veeva and IQVIA, and expand the team to meet growing demand from global pharmaceutical and medical device companies, including a Fortune 500 client already onboard.

Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo AI offers a new model of AI for highly regulated fields. Instead of “move fast and break things,” their approach centers on accuracy and compliance. Each life sciences expert is paired with a team of AI agents designed to execute complex workflows under human oversight. This empowers specialists to become the “CEOs” of their own processes, driving productivity without compromising standards.

“Many automation tools overlook the human expertise at the heart of life sciences,” said Udith Vaidyanathan, CEO of LogicFlo AI. “Our platform builds automation for people, enabling top scientists and regulatory professionals to focus on what truly matters—pushing science forward and improving patient outcomes.”

Before founding LogicFlo, Vaidyanathan led strategic business units within Abbott’s CEO office and left Harvard Business School to pursue this vision. CTO Arun Ramakrishnan brings experience from developing high-precision AI models for Intuitive Surgical’s Da Vinci robotic system used in real surgeries. “Traditional automation fails in life sciences because it’s rigid and disconnected from actual workflows,” Ramakrishnan explained. “LogicFlo’s AI agents are intelligent, modular, and tuned to the nuances of scientific work.”

LogicFlo marks a shift in enterprise software—from passive data repositories to interactive systems of engagement. Users work directly with AI agents that understand instructions, perform tasks, and deliver results, creating a seamless workflow experience. The platform is currently deployed in medical affairs, regulatory, commercial, and quality teams at global life sciences organizations. Early adopters report dramatic time savings: medical writing that once took weeks now completes in minutes, reducing time-to-first draft by up to 2000x. Medical information response times have shortened from one or two weeks to just days.

Unlike brittle or black-box automation, LogicFlo’s agents are built for regulated environments with full auditability and human-in-the-loop controls. They adapt to each organization’s templates, workflows, and compliance needs, collaborating as teams by breaking down work, validating outputs, and escalating to humans only when necessary.

“We are at a pivotal moment where AI agents can unlock real productivity in regulated scientific work,” said Vaidyanathan. Rohil Bagga, VP of Investments at Lightspeed, added, “LogicFlo AI’s platform empowers life sciences teams to create intelligent workflows that boost productivity across critical functions. The founders’ deep domain knowledge and technical expertise position them to transform this essential industry.”

With this funding, LogicFlo will expand its library of AI agents, enhance integration with life sciences-native platforms, and grow its team to meet sector demand. The company’s vision is to redefine what work feels like for every expert in life sciences. “If we can provide scientific professionals with a platform that moves at their pace, we enable them to accelerate medical breakthroughs,” Vaidyanathan concluded.